Sudarshan Pharma Industries Limited (SPIL) has made a strategic move to enhance its manufacturing capabilities in the pharmaceutical sector. The company has invested ₹25.5 crore to acquire an operational Active Pharmaceutical Ingredient (API) facility located in Telangana, signing a definitive agreement with Srigen Lifesciences Private Limited for the transfer of capital assets.

Strategic Acquisition Details

The acquisition includes land, buildings, and plant & machinery at a fully operational manufacturing facility situated in a strategic location in Telangana. This high-impact move is expected to result in significant growth in SPIL's manufacturing capacity and accelerate its trajectory in the high-growth API and specialty chemicals sectors.

Expansion of Product Portfolio

The newly acquired facility is capable of producing complex, high-margin molecules, which will enhance SPIL's offerings in global therapeutic markets. Some of the key APIs and intermediates that can be produced at this facility include:

• Ropivacaine
• Bupivacaine
• Probenecid (Probalan)
• Sitagliptin
• Apixaban
• Rivaroxaban

These products have strong demand across regulated and semi-regulated markets, positioning SPIL for expanded market presence.

Strategic Benefits

The acquisition brings several strategic advantages to Sudarshan Pharma:

1. Immediate Manufacturing Scale-Up: The facility adds instant production capacity, improving supply chain responsiveness and overall throughput.
2. Faster Time-to-Market: With established infrastructure and regulatory frameworks, SPIL can significantly reduce product launch timelines compared to greenfield projects.
3. Regulatory Advantage: The facility's proven compliance track record and comprehensive regulatory documentation are expected to shorten approval cycles and lower regulatory costs.

Management Commentary

Sachin Mehta, Joint Managing Director & Chief Financial Officer of SPIL, commented on the acquisition: "This investment represents a pivotal milestone in Sudarshan Pharma's growth agenda. It not only strengthens our manufacturing backbone but also significantly enhances our ability to serve global markets with agility, quality, and regulatory compliance. This addition is expected to contribute meaningfully to both revenue and profitability, supporting our financial performance and long-term shareholder value creation."

About Srigen Lifesciences

Srigen Lifesciences, established in 2010, is a research-driven pharmaceutical company specializing in the development, manufacturing, and commercialization of advanced API Key Starting Materials (KSMs) and intermediates. The company operates a well-equipped facility with an 80-kilolitre reactor capacity, supporting medium- to large-scale, multi-product manufacturing under stringent quality, safety, and regulatory standards.

Conclusion

This strategic investment by Sudarshan Pharma Industries Limited marks a significant step in the company's expansion plans. By acquiring an operational API facility, SPIL is poised to strengthen its position in the pharmaceutical and specialty chemicals market, both domestically and globally. The move aligns with the company's long-term strategy to build a robust, scalable, and compliance-driven manufacturing infrastructure, supporting its global expansion efforts and driving sustained value creation for stakeholders.

Sudarshan Pharma Industries announced the resignation of its Chief Financial Officer (CFO), Manoj Lodha, effective August 5, 2025. The company disclosed this information to BSE Limited in compliance with regulatory requirements.

Resignation Details

Manoj Lodha has decided to step down from his position as CFO to pursue a higher strategic role in a different industry/sector. In his resignation letter, Lodha expressed gratitude for the support received during his tenure and extended his best wishes for the company's continued success.

Company's Statement

The company confirmed that Manoj Lodha is not related to any directors of Sudarshan Pharma Industries. This clarification was provided as part of the standard disclosure process.

Transition Process

While the company has not yet announced a successor, it is expected that Sudarshan Pharma Industries will initiate the process of identifying a new CFO to ensure a smooth transition of financial leadership.

About Sudarshan Pharma Industries

Sudarshan Pharma Industries is a pharmaceutical company listed on the Bombay Stock Exchange (BSE). The company's registered office is located at 301, Aura Biplex, Above Kalyan Jewellers, S.V. Road, Borivali (West), Mumbai - 400092.

Investors and stakeholders are advised to monitor official company communications for further updates regarding the CFO transition and any potential impact on the company's financial strategy.